Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT9402-26-Q-9101
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The Department of Defense (DoD), through the Defense Health Agency, has issued a solicitation (Procurement Identifier: HT9402-26-Q-9101) for the establishment of Blanket Purchase Agreements (BPAs) and participation in the Uniform Formulary Additional Discount Program (UF ADP) related to its pharmacy benefits program. This initiative is mandated by 10 U.S.C. § 1074g and further defined by 32 CFR Section 199.21, which require the DoD to maintain an effective, efficient, and integrated pharmacy benefits program for the Military Health System (MHS). The program’s primary objective is to ensure the availability of clinically and cost-effective pharmaceutical agents for military beneficiaries.
The scope of this procurement centers on pharmaceutical agents within the oncological therapeutic class, specifically those indicated for the treatment of myelofibrosis. The agents identified for this solicitation include Inrebic, Jakafi, Ojjaara, and Vonjo. The DoD Pharmacy and Therapeutics (P&T) Committee will evaluate these agents for inclusion in the DoD Uniform Formulary (UF), considering both clinical effectiveness and cost efficiency. The outcome of this process will determine the classification of each agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF), which in turn impacts cost sharing and accessibility for beneficiaries.
Contractors responding to this solicitation are expected to provide quotations for the specified pharmaceutical agents, adhering to the instructions and requirements detailed in the attached Request for Quotation (RFQ) and its appendices. The RFQ outlines the process for submitting proposals, important deadlines, and the terms governing both the UF BPA and UF ADP agreements. A pre-quotation teleconference is scheduled for November 20, 2025, as described in Part 2.4 of the RFQ, offering an opportunity for interested parties to seek clarification and guidance prior to submission.
Key requirements for participation include the ability to manufacture and supply the listed oncological agents, compliance with all applicable federal regulations, and a demonstrated capacity to support the DoD’s integrated pharmacy benefits program. The procurement is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505, indicating a focus on pharmaceutical products. The place of performance is San Antonio, Texas, United States.
The contracting entity for this opportunity is the Defense Health Agency, a federal office responsible for managing health-related procurement for the DoD. Primary and secondary points of contact for this solicitation are Tracy Banks ([email protected]) and Stephanie Erpelding ([email protected]), respectively. The solicitation was posted on August 1, 2026, and responses are due by January 16, 2026.
This is a formal solicitation (SOLICITATION) and is currently active. Interested contractors should review the RFQ and all associated attachments available via the official notice URL (https://sam.gov/opp/276d0a5c639840cfbb8ed6f150086132/view) to ensure compliance with submission requirements and to assess alignment with their capabilities. No set-aside requirements or special considerations are specified in the provided information. The core elements of this procurement—supporting the DoD’s pharmacy benefits program, supplying specified oncological agents, and participating in formulary and discount programs—will remain constant throughout the contract lifecycle.
Documents7